Centessa Pharmaceuticals Statistics
Total Valuation
CNTA has a market cap or net worth of $1.75 billion. The enterprise value is $1.39 billion.
Important Dates
The next estimated earnings date is Tuesday, May 20, 2025, after market close.
| Earnings Date | May 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CNTA has 133.18 million shares outstanding. The number of shares has increased by 19.02% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 133.18M |
| Shares Change (YoY) | +19.02% |
| Shares Change (QoQ) | +13.59% |
| Owned by Insiders (%) | 0.38% |
| Owned by Institutions (%) | 61.48% |
| Float | 93.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.34 |
| P/TBV Ratio | 4.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.25, with a Debt / Equity ratio of 0.29.
| Current Ratio | 9.25 |
| Quick Ratio | 9.09 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -19.93 |
Financial Efficiency
Return on equity (ROE) is -73.93% and return on invested capital (ROIC) is -29.91%.
| Return on Equity (ROE) | -73.93% |
| Return on Assets (ROA) | -26.82% |
| Return on Invested Capital (ROIC) | -29.91% |
| Return on Capital Employed (ROCE) | -38.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.06M |
| Employee Count | 77 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CNTA has paid $2.84 million in taxes.
| Income Tax | 2.84M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +46.60% in the last 52 weeks. The beta is 1.54, so CNTA's price volatility has been higher than the market average.
| Beta (5Y) | 1.54 |
| 52-Week Price Change | +46.60% |
| 50-Day Moving Average | 14.06 |
| 200-Day Moving Average | 15.15 |
| Relative Strength Index (RSI) | 50.10 |
| Average Volume (20 Days) | 617,748 |
Short Selling Information
| Short Interest | 5.33M |
| Short Previous Month | 5.20M |
| Short % of Shares Out | 4.70% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.51 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -201.06M |
| Pretax Income | -163.67M |
| Net Income | -235.76M |
| EBITDA | -200.71M |
| EBIT | -201.06M |
| Earnings Per Share (EPS) | -$2.06 |
Full Income StatementBalance Sheet
The company has $482.18 million in cash and $117.83 million in debt, giving a net cash position of $364.35 million or $2.74 per share.
| Cash & Cash Equivalents | 482.18M |
| Total Debt | 117.83M |
| Net Cash | 364.35M |
| Net Cash Per Share | $2.74 |
| Equity (Book Value) | 401.55M |
| Book Value Per Share | 3.03 |
| Working Capital | 478.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$142.06 million and capital expenditures -$34,000, giving a free cash flow of -$142.09 million.
| Operating Cash Flow | -142.06M |
| Capital Expenditures | -34,000 |
| Free Cash Flow | -142.09M |
| FCF Per Share | -$1.07 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |